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ABSTRACT Determination of a macromolecular structure using x-ray diffraction is a multistep process that involves a plethora
of techniques involving molecular biology, bioinformatics, and physical sciences. Counterintuitively, the success of any or all
individual steps does not guarantee the success of the overall process. This review examines the difﬁculties presented by each
step on the path from a gene to the ﬁnal publication, together with certain lucky (or unlucky) circumstances that can affect the
velocity along that path.
INTRODUCTION
From its beginnings up to this day, protein crystallography
(and, consequently, structural biology as a whole) owes a lot
to fortunate events. The first such fortuitous circumstance
was the lack of tenure system at the University of Cambridge,
UK. This allowed Max Perutz to study the structure of he-
moglobin for more than 20 years before the first significant
structural results could be published (1). His work, however,
allowed the development of a completely new methodology
which was later used by all other groups investigating protein
structures, and also led in 1962 to the award to Perutz of a
Nobel Prize in chemistry. Moreover, the choice of hemoglo-
bin as a target of that effort was a lucky one, as an unusually
high fraction of the secondary structure of that protein is
a-helical, which makes it very rigid, stable, well-diffracting,
and comparatively easy to model.
Later, the development of synchrotrons by high-energy
physicists catalyzed the explosion of protein structures
solved by x-radiation. The orbiting particles, either electrons
or positrons, generate what used to be called, in the early
years, parasitic radiation. Thus, a small hole in the synchro-
tron wall could provide a source of x-radiation much stronger
than any conventional generator. A number of dedicated
synchrotron x-ray sources have been built all over the world
since the early 1980s, followed by third-generation machines
that generate x-rays not only by simple circulation of parti-
cles around the rings, but also by employing insertion devices
called wigglers and undulators.
Thus, at present, crystallographers have access to more
than 100 dedicated x-ray beamlines, located on 22 synchro-
trons that have been constructed on all continents, except for
Antarctica. How successful have they been? The synchrotron
sources were responsible for a total of 3897 structures in
2005, more than three-quarters of all macromolecular struc-
tures published that year (Fig. 1). Some structures were
solved in a matter of hours, if not minutes, after crystals were
placed in the synchrotron beam (2). Obviously, however,
only lucky events were reported, as on the average a single
solved and deposited structure must have required roughly
40 h of synchrotron time (assuming 2000 h of synchrotron
operation per year), as well as many priceless crystals.
The advancement in x-ray sources was accompanied by
the development of fast x-ray detectors and by great ad-
vancement in computational methods and computer tech-
nology. All these developments also took place during the
period of unprecedented progress in the techniques of mo-
lecular biology. Inexpensive workstations or even laptops
have the computational power necessary to solve most crys-
tallographic structures, and extremely sophisticated software
is able to elucidate the three-dimensional structure even when
very poorly diffracting crystals are used. Structure elucidation
for a macromolecule is a multistep process (see Fig. S1 in
SupplementaryMaterial, Data S1) that requires 100% success
at every step. A major difficulty in protein crystallography is
that the success of a particular step can only be fully evaluated
at the next step, or sometimes even two or three steps later.
The experimenter may find it necessary to return to a previous
(or possibly even the initial) step to achieve ultimate success.
This iterative process of structure solution may take as long
as 10–20 years of battle on various fronts. Some of our own
projects that took very long to complete include, for example,
the structure of nerve growth factor solved 17 years after
crystals became available (3,4), or that of L-asparaginase,
solved 19 years after initial crystallization (5,6). In some areas
of structural genomics, however, where there is the option to
drop a stubborn target, structure solution of a set of many
targets can be compared to Napoleon’s war with Russia.
Napoleon did not lose a single battle, but lost the war of
attrition, a term frequently used for description of the progress
in structural genomics. The most productive centers were
those that managed to win the war of attrition, not those that
were the best in performing one or more steps (7,8). In this
review, we will examine the difficulty presented by the vari-
ous steps on the path from a gene to the final publication that
should describe not only the structure, but also the mechanism
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of action of a macromolecule and also the lucky (or unlucky)
circumstances that can affect the velocity along that path.
From gene to crystal
Even in a high-throughput structural genomics center, the
first step is a detailed analysis of all available data for a
protein target, through bioinformatic and/or experimental
approaches. Sometimes the experimental knowledge about a
protein is nonexistent or very limited, but still there are many
bioinformatic tools capable of extracting useful information,
even when the gene sequence provides the only available
information. For example, these tools often allow elimination
of intrinsically unstructured proteins in the early stages of the
process. It is generally agreed that work on mammalian and/
or membrane proteins is much more challenging than on
soluble bacterial proteins, but even a ‘‘simple’’ bacterial
protein can cause a lot of trouble and may require substantial
effort for structure solution. Even more challenging than
studies of integral membrane proteins may be projects in-
vestigating the structure of various macromolecular com-
plexes. Despite significant amounts of pure luck, solving
such structures may take years. To give an example, ribo-
somal particles were crystallized as early as 1982 (9), but the
first detailed structures were not completed until 2000 (10).
Cloning is a relatively straightforward step that is facili-
tated by a plethora of commercially available kits and ser-
vices, including de novo gene synthesis. Synthetic genes with
optimized codons (11) may improve the yield of protein,
especially when they are expressed in a system utilizing
different codon frequencies than their native genome. At first
glance, the criterion for success of this step seems to be a
simple one—either the gene is successfully cloned or not.
Unfortunately, quite often problems encountered later, such
as low expression level, lack of protein solubility, unsuc-
cessful crystallization, or problematic properties of the
crystals (e.g., twinning, low resolution diffraction) may result
in the need to repeat the cloning step, despite its apparent
success.
Constructs must be designed with the assumption that the
protein itself should be treated as one of the most important
factors that affect crystallization (12), and that structural
analysis might require milligrams of protein. Why it is worth
spending time choosing an appropriate expression system
and vector? First of all, information about whether the protein
folds properly by itself (13) or folds only under some special
conditions (14,15) can influence vector design. For example,
the target protein may require the presence of an additional
protein which would act as a folding chaperone, protect it
from degradation during expression, or assist in forming di-
sulfide bonds (16). Crystallization experiments can take as
long as weeks or months, so the protein should be stable for
long periods of time. Proteins, especially those from eukary-
otes, are frequently posttranslationally modified. In such
cases, expression in a bacterial system may sometimes result
in inactive protein, yet even that apparent failure could be ad-
vantageous for crystallization when, for example, the protein
is not glycosylated (17). Proteins containing disulfide bonds
(18) are especially difficult to express in the properly folded
form when bacterial systems are used. Some proteins which
are only expressed in inclusion bodies can be purified under
denaturing conditions and then refolded, and consequently
much attention has been paid to development of new re-
folding protocols (19). When refolding fails, the only choice
is to select a different expression protocol (15) or expression
system.
Sometimes the inability to purify and/or crystallize an in-
tact protein may force the experimenter to switch tactics and
choose a fragment (20) as a target for structure determination.
Limited proteolysis is the technique of choice in determining
the domain boundaries in multidomain proteins, but it is
sometimes very difficult to choose a fragment of a protein that
will be stable and represent a single domain. It can be difficult
to make mammalian proteins in bacteria, and in many cases it
is necessary to resort to the application of yeast, insect, or
mammalian cells as expression systems. At all these stages we
must think about the final goal of the experiment—elucidation
of a three-dimensional structure that represents a biologically
relevant form.
Once the yield of protein expression is deemed to be ac-
ceptable, the protein has to be purified. A hundred years ago,
scientists used crystallization to purify proteins, as illustrated
in a beautiful book showing hundreds of photographs of
hemoglobin crystals (21). These days, it is assumed that to
crystallize stubborn proteins, the sample must be homoge-
neous, not only in terms of the polypeptide sequence, but also
in terms of protein folding, conformation, and possibly ag-
gregation. To simplify protein purification and increase its
speed, recombinant proteins are often fused with polypep-
tides or even full-size protein partners that facilitate affinity
chromatography. By far the most popular purification
FIGURE 1 The fraction of x-ray structures deposited in the PDB that
report the use of synchrotron sources for their determination (dark blue) and
sample temperatures close to 100 K during data collection (light blue).
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method (22) involves addition of a poly-histidine tag (His-
tag) (23) in combination with metal-ion affinity chromatog-
raphy (24). Such a tag consists of 6–10 histidine residues,
usually followed by a spacer that allows subsequent cleavage
by a suitable protease. One of the advantages of the His-tag is
its relatively small size, meaning that sometimes the tag need
not be removed before crystallization (25). Addition of fusion
proteins often increases both the level of protein expression
and its solubility. Fusing maltose-binding protein, thio-
redoxin, glutathione-S-transferase, or green fluorescent pro-
tein may be in many cases advantageous, and these proteins
can be used alone or in combination with a His-tag (26).
Moreover, the presence of a fusion partner, in particular
maltose-binding protein, may help to properly fold the pas-
senger protein (27).
Crystallization requires samples of a protein in milligram
quantities, although with sufficient luck, combined with new
nanotechnologies, the amount of protein required to find the
initial crystallization conditions might be significantly re-
duced (28). Unfortunately, nanoliter technologies often pro-
duce crystals that are too small for x-ray structure analysis.
The transfer of nanoliter crystallization conditions to the
microliter scale is not always straightforward and the nature
of the difficulties in scaleup is not fully understood (although
development of in-chip techniques (29) may change that
situation). Initial screening is most often performed using the
sparse matrix method (30), and a variety of commercial
screens optimized for the crystallization of proteins (31,32),
nucleic acids, macromolecular complexes (33), or membrane
proteins are currently available. If the experimenter is lucky,
after setting up several hundred crystallization conditions she
or he may start optimization of crystal growth. The process of
crystal optimization can be performed in many ways, and in
most common approaches, grid screen designs (34) based on
the initially obtained conditions are used. Other approaches
involve addition of so-called additives—usually small-mol-
ecule compounds—to the crystallization media (35). Less
fortunate experimenters who failed in finding any conditions
for crystal growth may try reductive methylation of lysine
residues (36) before they return to designing new protein
constructs. In cases where reductive methylation fails, se-
quence mutation(s) could be the next choice for increasing
crystallizability of a protein (22,37), but such an approach
requires return to the beginning of the path. An alternative
rescue strategy is the use of in situ proteolysis (38).
Twenty years ago, once a crystal was grown, it was placed
in a sealed capillary in the presence of its mother liquor and
was used for diffraction experiments conducted at room
temperature on a laboratory-based x-ray source. Now, how-
ever, a vast majority of the diffraction experiments are
performed at synchrotrons (Fig. 1). The flux at some high-
intensity beamlines is so high that an unprotected crystal
would evaporate in milliseconds. Even relatively low-inten-
sity synchrotron beams induce radiation damage (39), and
may cause a variety of chemical modifications of the protein
(Fig. 2). The most efficient way of slowing down that process
is cryocooling (40), which, in connection with a very simple
method of crystal mounting using the so-called cryo-loops
(41), has revolutionized data collection (Fig. 1). During
cryocooling, crystals protected by cryosolutions are rapidly
transferred to a nitrogen stream maintained at a temperature
near 100 K. Under such conditions, the solution around and
inside the crystal is glassified. The cryosolutions may contain
different types of alcohols, salts, or oils that prevent ice
formation which would destroy the order of macromolecular
crystals. Crystal freezing, although relatively simple, requires
testing of several different cryosolutions, but even exhaustive
cryocooling experiments may produce samples of much
lower quality than the original crystals. Altering the crystal
environment, especially by controlling the humidity or by
annealing, may dramatically improve crystal quality. Re-
cently, there have been many reports about the use of a credit-
card approach, although no financial transactions are in-
volved. A piece of thin plastic (a credit card would do quite
well) can be used to block the cryostream for several seconds
and anneal the crystal (42). Annealing may lead to dramatic
improvement of diffraction quality (see Fig. S2 in Data S1),
but such a result is by no means guaranteed. Thus, we would
FIGURE 2 Residue 160 in the crys-
tal structure of soybean lipoxygenase
shown together with 2Fo-Fc electron
density map. (A) A map contoured at
1s level. The crystal was obtained
using natural protein isolated from soy-
beans and the residue was identified as
serine (PDB codes: 1YGE and 1F8N).
(B) Map shown at 0.7s. The serine
was replaced by glutamic acid, what is
consistent with results of the DNA
sequencing (Ted Holman, 2007, private
communication). (C) Electron density
shown at 0.3s. Different contouring of
the map reveals either possible decar-
boxylation during data collection or
conformational flexibility of Glu160.
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not like to recommend such an approach in cases where data
quality is questionable, but only one crystal is available, and
the experimenter has doubts whether the crystallography
gods will smile on him/her on that particular day.
From diffraction images to electron density map
Placement of a crystal in the x-ray beam initiates the last
experimental step of the process of structure determination.
In principle, this experiment is a very simple one, so it is
believed that data collection should be easy and straightfor-
ward to automate, as there are only a very few parameters that
are under control of the experimenter. These parameters in-
clude crystal/detector distance, exposure time, oscillation
angle, and wavelength of x-radiation. However, there are at
least three additional parameters that are beyond the experi-
menter’s control: crystal quality (long-range order, mosaic
spread), radiation decay, and limitations of the experimental
setup (e.g., detector dynamic range, goniostat precision, etc.).
The difficulty of choosing user-controlled parameters that
minimize the detrimental influence of crystal quality and
radiation decay is illustrated by analysis of the data collected
on one of the ALS beamlines. Data from this beamline show
that, on average, it is necessary to collect 57 full data sets (43)
to make one PDB deposit, and the number of tested crystals is
even higher. The experimental difficulty lays in the fact that
the result of a diffraction experiment is a set of diffraction
intensities (or amplitudes), not the phases that are necessary
for calculation of the electron density map.
In the current practice, diffraction data are collected for
three major types of calculations: molecular replacement
(MR), multiple anomalous diffraction (MAD)/single anom-
alous diffraction (SAD), and the final refinement of the
model. The previously popular multiple isomorphous re-
placement has been overshadowed by the use of techniques
based on anomalous scattering. In the case of MR experi-
ments (44), the source of phases is a model of the same or a
similar protein, and the accuracy of the measured intensities
is much less important than obtaining a complete set, without
the loss of strong peaks through oversaturation of the de-
tector. For solution of new structures by the SAD, MAD, or
even multiple isomorphous replacement techniques, the
phases are derived from the differences between the observed
diffraction intensities and thus their accuracy is of utmost
importance. Data collection for the final model refinement
has a simple goal—to collect complete, high-accuracy data to
the resolution limit of diffraction. The latter experiment
seems to be the easiest one, but even it requires careful
planning, as improvement of statistical accuracy of measured
intensities does not necessarily result in better data (longer
counting time may increase radiation damage).
Traditionally, SAD/MAD experiments which require
highly accurate data were considered to be particularly dif-
ficult, but development of experimental hardware, software,
and protocols has increased substantially the percentage of
structures solved by these techniques. Since a SAD experi-
ment involves collecting only a fraction of data required for
MAD, it should be expected that the former method would be
preferable, but the differences between various regions of the
world in the use of these techniques show that proliferation of
the most efficient experimental protocols is slow (Fig. 3).
SAD/MAD experiments rarely fail just because of the lack of
a sufficient number of atoms that produce anomalous signal
(except when very weak anomalous scatterers such as sulfur
are used), but more often due to experimental errors, in-
volving too many saturated detector pixels (overloads), or an
improper data collection strategy that may result in premature
radiation damage and/or incomplete data. Even small errors
at this stage mean significantly more work for the experi-
menter during structure solution and refinement. In many
cases, less than optimal diffraction experiments have to be
repeated. The completeness of low resolution data is quite
often neglected (PDB deposits report completeness in the
highest resolution shell but not in the lowest), resulting in
difficulties during structure solution and model building.
Sometimes, given pure luck and experience, one may still
recover from such problems using nonstandard approaches
(45), but it has to be stressed that accurate, nonsaturated low-
resolution data are critical for both the MR and SAD/MAD
techniques. It is sometimes a surprise that structure can be
solved using data from a lower quality crystal, rather than
from a set collected on a high quality crystal. Low quality
crystals diffract weakly and consequently do not produce
overloaded low resolution reflections. In that case the order in
which crystals are chosen for the diffraction experiments may
determine the probability of the final success, as rarely do
experimenters collect another complete data set when they
have already seen ‘‘perfect’’ diffraction.
In the last several years, interpretation of experimental
results has been greatly facilitated by several integrated
software packages such as CCP4 (46), PHENIX (47), or
HKL-3000 (48), coupled with the availability of fast com-
FIGURE 3 Comparison of the extent of application of SAD and MAD
techniques in APS and ESRF, as reported in PDB.
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puters that allow for almost real-time, on-the-fly calculations.
The methods applied to solution of the phase problem, al-
though quite complicated, are hidden behind sophisticated
software and (sometimes even more sophisticated) user in-
terfaces that can occasionally make a noncrystallographer a
competent and efficient structure solver. In simple cases, an
interpretable initial electron density map may be obtained
with just a few clicks of a mouse.
Most often, the initial phases (and, as a consequence,
electron density maps) obtained in SAD/MAD or MR ex-
periments are not very accurate, and their interpretation could
be very difficult. Luckily, several phase improvements
methods have been developed that, when properly applied,
may dramatically increase the quality of the electron density
maps. Solvent-flattening methods and noncrystallographic
symmetry averaging are especially popular. It is worth
mentioning that although crystals with high solvent content
often diffract poorly (49), nevertheless the high solvent
content may turn out to be advantageous and help produce a
high quality initial map. Dramatic changes in the quality of
electron density maps can be observed when noncrystallo-
graphic symmetry averaging is applied, so the presence of
many (but not too many) copies of a macromolecule in an
asymmetric unit should not be considered bad luck.
Even in the cases of properly performed data collection,
the nature of the crystals may introduce problems that prevent
structure solution. One of the most vexing problems is caused
by twinning, a phenomenon that arises when more than one
lattice diffracts simultaneously. It was recently reported (50)
that the combination of crystal and lattice symmetries could
allow twinning in more than 30% of cases of the structures
reported in PDB. Moreover, twinning is not always noticed,
and in some situations prevents structure solution. If that
happens, there is no other choice than to return to the labo-
ratory and grow a new crystal form of a particular macro-
molecule.
Model building, reﬁnement, and
structure validation
In the current practice not only are the initial electron density
maps generated in an automatic or semiautomatic manner by
software, but also the interpretation of the resulting electron
density may be done almost automatically. Several programs,
including ARP/wARP (51), RESOLVE (52), and MAIN
(53), use different approaches to automated model building.
Manual model building and adjustment also become rela-
tively easy, thanks to powerful graphics software such as O
(54) and COOT (55). However, it is still not trivial to interpret
the electron density maps obtained at low resolution (espe-
cially below 3.2 A˚).
Final refinement of macromolecular structures is usually
accomplished with programs such as CNS/CNX/X-PLOR
(56), REFMAC (57), and SHELXL (58). Structure refine-
ment is comparatively easy if data extend to between 1.5 and
2.4 A˚. Refinement with very high resolution data can be time-
consuming due to the wealth of structural details that have to
be modeled (such as multiple conformations of the side
chains, complicated temperature factor models, etc.). Very
low resolution structures (below 3.2 A˚) are in a separate class,
requiring very careful refinement and validation. Another
type of difficulty in refinement arises when a structure con-
tains moieties other than amino acids, such as metal ions and
small molecule compounds. Although identification and re-
finement of metal ions present in protein structure seems to be
comparatively straightforward (59), many new structures
reported in the PDB still contain metal ions with very
improbable coordination or geometry of the metal-binding
environment. Protein-DNA or protein-ligand complexes may
pose additional difficulties as automatic model building
works best for amino-acid chains. A refinement strategy
depends mostly on resolution, and the resolution also deter-
mines how many parameters may be refined, and how they
should be treated (60).
Refinement and manual structure rebuilding or adjustment
has to be performed together with model validation. As men-
tioned above, significant advances in software allow many
noncrystallographers to collect data, as well as solve and
refine x-ray structures, without advanced knowledge of the
underlying techniques. Especially in such cases, sophisti-
cated tools for structure validation are necessary. Validation
tools should not only detect serious crystallographic and
chemical errors in the models, but should also be able to
guide an inexperienced person and suggest how to correct
errors. Examples of such programs are PROCHECK (61),
WHATCHECK (62), MOLPROBITY, and KING (63).
Sometimes experimenters ignore clear warnings from the
validation programs even during the process of deposition in
PDB, presumably since they are convinced that their struc-
ture is so special that any violations of known chemical rules
simply support its uniqueness. Unfortunately, only a very
small percent of lucky scientists observing novel chemistry in
their structures will ultimately hear from the Nobel Com-
mittee, but the unlucky ones will find sooner or later that the
validation tools will ruin their claims. Since deposition of
structure factors is now required in practically all publicly
funded research, other crystallographers can now routinely
use the ultimate validation tool, i.e., re-evaluation of ques-
tionable structures, so it is unlikely that the wrongly refined
structures will be able to pollute the databases in the future.
Interpretation of a model
It should be always remembered that the ultimate aim of a
crystallographic experiment, even if conducted under the
umbrella of structural genomics, is not creation of just a
model consisting of the atomic coordinates, but rather pro-
viding guidance to interpretation of chemical and biological
information. However, interpretation of the models should be
done in a way that takes into consideration their limitations
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imposed by factors such as, for example, data resolution,
overall quality of the model as indicated by R/Rfree, as well as
its chemical correctness. Moreover, it is worth stressing that
the final model does not represent a single molecule, but is a
time and space average from many molecules. High energy
radiation, particularly originating from very bright synchro-
tron beamlines, is able to cause chemical modification of
molecules, and, as shown in Fig. 2, even a model obtained
from high resolution data cannot be treated as error-free. At
low resolution, misinterpretation of the electron density is
relatively easy, and a careless approach to such data may
result in tracing a fragment of the amino-acid chain in the
opposite direction, or, very rarely, producing a completely
incorrect model. Moreover, the representation of numeric
values in the atomic coordinates deposited in the PDB format
(three digits after the decimal point) may be very misleading
to an inexperienced experimenter, who may assume that all
digits are significant and analyze the structure according to
that assumption (64–66). Analysis of structures deposited in
the PDB should take into account that the models contain
different types of errors which accumulated during the whole
process of structure determination, so interpretation of a
three-dimensional structure and all chemical or biological
conclusions derived from it are strongly affected by the
quality of the model. In particular, deduction of a detailed
mechanism of an enzymatic reaction requires knowledge of
the hydrogen-bond network in the macromolecule of interest.
Unfortunately, only the luckiest experimenters who are able
to determine a protein structure at very high resolution may
directly observe hydrogens in their structures. For most
structures (60% of the structures in PDB are between 1.7 and
2.5 A˚ resolution), the interpretation is not direct and a single
structure may support multiple chemical or biological reac-
tion mechanisms. A similar problem has to be solved by a
translator of poetry. Translation is an art, and a poem trans-
lated into a new language may even be better than the orig-
inal. Similarly, reinterpretation of a structure is quite often
much better than the original. The process of moving from
the coordinates to interpretation of the mechanism of action is
the most difficult step.
Is the structure biologically relevant?
Once the structure has been solved at high resolution, with
low R factors and small departure of the geometric parame-
ters from the library values, how confident can we be that it
describes a biologically relevant state of the protein? That
question has been asked (and answered) many times since the
beginning of protein crystallography. It is actually not a
single problem, but at least two interrelated ones. The first,
and maybe the easiest one to answer, is the question of
whether the structure of a protein in the crystal (solid state) is
the same as in solution. An early example was provided by
careful analysis of the structures of a small helical cytokine,
interleukin-4, solved independently in four laboratories. Two
structures of this protein were obtained by crystallography,
and two other by NMR. Their comparison has clearly shown
that the differences between these structures were due more
to the uncertainties in their determination (much larger for
NMR than crystallography) than to any variations in the
proteins (67). Thus, although this is a legitimate concern and
still needs to be answered separately in each specific case, a
general answer is that usually the differences between solu-
tion and solid state of proteins are small, if any.
Another part of the question, though, deals with the rele-
vance of the observed structure for the explanation of the
biological properties of the molecular system under study,
and it does not have a unique answer. Let us consider an
enzyme and the details of the reaction that it catalyzes.
Clearly, the structure of the apoenzyme may not be sufficient
to describe all steps of the reaction, since parts of the active
site may adjust to the presence of the substrate, transition
state, and product, and the nature of such changes is not al-
ways easy to predict. In particular, the structure of the tran-
sition state would be most illuminating, but by definition it is
not directly accessible, since it is unstable on the crystallo-
graphic timescale. Utilization of transition state mimics and
extremely fast data collection using Laue crystallography
(68) can help, but they still do not provide a guarantee that the
state of the protein observed in the crystal can directly explain
its biologically relevant properties, since proteins are by no
means stationary.
A relevant example of a plethora of difficulties encoun-
tered in determining the biological properties of a protein
based on crystallographic investigations is provided by the
ATP-dependent protease Lon. Although the enzyme has been
known for more than 20 years and its crystallographic in-
vestigations span a decade, the full-length Lon has resisted
crystallization (69). However, since the domain structure of
Lon has been determined, its individual domains have been
crystallized and analyzed separately. This work yielded a
number of surprises. For example, the structure of the active
site was significantly different in the catalytic domain of Lon
isolated from different bacterial sources, and it was initially
suggested that these differences might play a biological role
(70). However, subsequent crystallographic and mutagenesis
studies yielded a rather different picture, suggesting that none
of the structures of the apoenzyme show the active site in a
biologically relevant state, as the presence of a substrate or a
product of the reaction is likely to reorganize it very signif-
icantly. Since no good and specific substrates of Lon are
known, the details of its mechanism of action are still not
understood, even though an atomic-resolution structure of its
catalytic domain is available (71). Even more difficult is
analysis of the biological properties of the N-terminal domain
of this protein, most likely involved in substrate binding.
Crystal structure of the construct containing just over 100
residues indicated a novel fold, not found in any known
protein complexes and thus no conclusions about the mode
of binding could be drawn (72). However, a structure of a
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hypothetical protein from Bordetella parapertussis, BPP1347,
deposited in the PDB by the Northeast Structural Genomics
Consortium, has shown very significant topological similarity,
despite very low sequence similarity. This example illustrates
a common problem with some structural genomics-derived
structures, namely a difficulty of assigning the function to
proteins with novel fold (and that, incidentally, is one of the
stated reasons for these undertakings), but even structures
obtained in targeted efforts may not fare much better.
SUMMARY
In structural biology, the path from gene to publication most
often requires a significant amount of work and much luck. In
many cases, the period between obtaining the initial crys-
tallization conditions and publishing a structure may extend
over a decade. The bottlenecks of the whole process as well
as the frequently-used term, ‘‘high-hanging fruit,’’ are being
constantly redefined. The major difficulty is the same as in
any other cutting-edge experimental science—the extraction
of a low signal from high noise. Nowadays, the whole pro-
cess of determining macromolecular structures is faster then
ever (see Fig. S3 in Data S1). We predict that, although the
proliferation of the best experimental protocols and the de-
velopment of new methodologies will decrease crystallogra-
phers’ dependence on fortunate circumstances, luck will still
play a significant role in the foreseeable future.
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